"Tetrahydroisoquinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of ISOQUINOLINES in which the nitrogen containing ring is protonated. They derive from the non-enzymatic Pictet-Spengler condensation of CATECHOLAMINES with ALDEHYDES.
| Descriptor ID |
D044005
|
| MeSH Number(s) |
D03.633.100.531.820
|
| Concept/Terms |
Tetrahydroisoquinolines- Tetrahydroisoquinolines
- Tetrahydro-Isoquinolines
- Tetrahydro Isoquinolines
- 1,2,3,4-Tetrahydroisoquinolines
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydroisoquinolines".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydroisoquinolines".
This graph shows the total number of publications written about "Tetrahydroisoquinolines" by people in this website by year, and whether "Tetrahydroisoquinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2017 | 2 | 4 | 6 |
| 2018 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Tetrahydroisoquinolines" by people in Profiles.
-
Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation. Eur J Med Chem. 2019 Feb 15; 164:317-333.
-
Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci. 2018 Dec 01; 214:118-123.
-
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. J Clin Oncol. 2017 Oct 10; 35(29):3347-3353.
-
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017 Aug 22; 117(5):628-638.
-
Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey. Int J Gynecol Cancer. 2017 07; 27(6):1141-1148.
-
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017 06; 18(6):812-822.
-
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project. Support Care Cancer. 2017 06; 25(6):1743-1748.
-
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. Br J Cancer. 2017 01; 116(3):335-343.
-
Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs. 2015 Jul; 26(6):678-81.